Medicare will charge $121.60 a month in 2026 for beneficiaries who keep only immunosuppressive drug coverage after losing standard Medicare eligibility following a kidney transplant. The Centers for Medicare & Medicaid Services set that figure in the same November announcement that raised the standard Part B premium to $202.90 and the annual deductible to $283 for the year ahead. The narrow benefit exists because Medicare coverage tied to a transplant normally ends 36 months after the surgery, leaving a gap for people who still need lifelong anti-rejection medication but no longer qualify for full Part B on any other basis. For those beneficiaries, the premium buys drugs and nothing else.
How the Immunosuppressive-Drug-Only Premium Works
The immunosuppressive-drug-only benefit is not a separate insurance product; it is a narrow continuation of Part B enrollment carved out for one population. Since 2023, CMS has allowed individuals whose full Medicare coverage ended 36 months after a kidney transplant, and who do not have other qualifying coverage such as an employer group health plan, Medicaid, or a Marketplace plan, to keep paying into Part B for the sole purpose of covering the immunosuppressive drugs a transplant recipient must take for the rest of their life.
That election carries its own separate premium, set apart from the standard Part B rate everyone else pays. The standard monthly charge for 2026 is $121.60, and CMS applies it uniformly to every beneficiary enrolled in the drug-only pathway regardless of which anti-rejection medication a person’s transplant team has prescribed. The premium buys the drug coverage only; it does not restore eligibility for the doctor visits, hospital stays, lab work, or durable medical equipment that a Medicare beneficiary with full Part B coverage would otherwise receive.
That structure explains why the drug-only premium is so much lower than the $202.90 rate covering the full range of Part B services. Because the benefit pays for medication alone rather than the broader mix of physician and outpatient services the standard actuarial rate is built to cover, CMS prices it at roughly 40 percent below the standard premium. A transplant recipient who ages out of full coverage and enrolls only in the drug benefit trades a smaller monthly bill for a much narrower scope of what Medicare will pay for going forward.
Where the help is written down: The programs that lower Medicare costs each run on a different form and a different office, and no single notice lists them together. See the state cost-help packs in The Medicare Cost & Coverage Protection Kit.
Why Coverage Ends 36 Months After a Transplant
Kidney failure is one of the few diagnoses that qualifies someone for Medicare regardless of age, through the End-Stage Renal Disease pathway. That eligibility is not open-ended. CMS’s own premium notice describes the underlying rule directly: coverage tied to a successful kidney transplant ends 36 months after the transplant, and a recipient who has since returned to work, moved off disability-based eligibility, or otherwise no longer qualifies for Medicare on another basis loses full Part B coverage entirely at that point — doctor visits, hospital care, and everything else Part B pays for.
What does not end at the 36-month mark is the medical need. A transplanted kidney depends on immunosuppressive drugs such as tacrolimus and mycophenolate indefinitely; missing doses is one of the fastest routes back to organ rejection, and rejection can mean returning to dialysis or needing a second transplant. Before the drug-only option existed, a recipient who lost ESRD-based Medicare eligibility and had no other insurance could face the full retail cost of daily anti-rejection medication, a bill that for some regimens runs into the thousands of dollars a month.
The 2023 option closes that specific gap without reopening full Medicare eligibility. A person who qualifies can keep paying the $121.60 premium indefinitely as long as they continue to meet the requirement of having no other qualifying insurance, and the benefit follows the person rather than a calendar deadline — there is no expiration date built into the drug-only coverage itself, only the ongoing monthly premium and the underlying prescription need that made the benefit necessary in the first place.
How the $121.60 Premium Rises With Income
Like every other Medicare Part B premium, the $121.60 baseline is not the final number for every beneficiary. CMS applies the same income-related monthly adjustment structure to the drug-only benefit that it applies to full Part B coverage, scaled down to match the smaller base premium. An individual filer with modified adjusted gross income above $109,000 pays more than the standard rate, and the surcharge climbs through the same six brackets CMS uses for full Part B, reaching a $608.10 total monthly premium for individual filers reporting $500,000 or more.
The dollar adjustments are smaller than the surcharges added to full Part B coverage — the top income bracket adds $486.50 to the drug-only premium, compared with $487.00 added to the standard premium — but the income thresholds that trigger each bracket are identical across both benefits. CMS estimates the income-related adjustment affects roughly 8 percent of people enrolled in Medicare Part B overall, a share that includes the smaller population paying only for immunosuppressive drug coverage rather than the full Part B benefit.
CMS published all of these figures together in its 2026 Medicare Parts A & B Premiums and Deductibles fact sheet, released November 14, 2025, the same document that set the standard Part B premium, the Part A hospital deductible, and every income bracket governing both benefits for the year ahead. No later CMS guidance has revised the $121.60 figure, and the agency’s fact sheet remains the controlling federal notice for what a transplant recipient enrolled only in drug coverage will owe each month in 2026.
Coverage After a Transplant Window Closes
The $121.60 premium keeps immunosuppressive drug coverage alive after a transplant recipient’s broader Medicare eligibility ends, but it does not say which other state or federal programs might lower the cost of the drugs themselves, or what a Part D or Medicare Advantage plan requires before it approves a prior authorization for a transplant medication. Those rules sit in state-specific guidance and plan-level appeal processes that a CMS premium notice never covers.
The Medicare Cost & Coverage Protection Kit is a 10-page kit with 51 state Medicare cost-help packs and the prior-authorization appeal steps for cases like a denied transplant-drug claim.
See The Medicare Cost & Coverage Protection Kit.
This article was researched and drafted with the assistance of AI and reviewed by The Money Overview editorial team.
